Procyrion, Inc.’s Post

ROSEAId Inc., Welcomes Joseph Rossi as CEO! Joseph Rossi brings visionary leadership and decades of experience, including serving on Boards of Directors and Advisory Councils, to his role as CEO of ROSEAId Inc. Driven by his passion for leveraging technology, he is excited and aims to enhance the overall healthcare experience for patients and providers alike. To learn more, please refer to the attached press release below! #ROSEAId #biomedical #leadership #digitaltransformation #biotechnology #telepathology Russell Raff Harvey Rand Eli Zukovsky Venkat Iyer Jen Flaherty

I love pointing to the successes in #medtech. Usually startups and emerging companies are easy examples as they are relatively linear in their growth. Today, would like to shine the light on a company that reinvented itself. Had heard about companies doing this in the past, this was the first time I knew the players involved. Pulse Biosciences, Inc. shifted their focus from an aesthetic indication to #PFA or pulse field ablation. Seismic in nature. Seems to be a combination of leadership, collaboration and sheer will that has brought them closer to success. To take this massive leap it took support from their board/investors (Bob Duggan) and the fortitude of their CEO at the time (Kevin Danahy) and the determination of the team (Darrin Uecker David Danitz Patty Perla, PHR William Knape Justin Lerman Mitch Levinson Mike Smith Vincent Havart ) to bring them to this point. 510k clearance and now first case under their belt. Blue skies ahead. Looking forward to watching Burke T. Barrett continue their momentum and take them to new heights. This has been a case study that should be read by any company looking to change direction. Extraordinary effort. https://lnkd.in/eWi2eQSA

ROSEAId Inc., Welcomes Joseph Rossi as CEO! Joseph Rossi brings visionary leadership and decades of experience, including serving on Boards of Directors and Advisory Councils, to his role as CEO of ROSEAId Inc. Driven by his passion for leveraging technology, he is excited and aims to enhance the overall healthcare experience for patients and providers alike. To learn more, please refer to the attached press release below! #ROSEAId #biomedical #leadership #digitaltransformation #biotechnology #telepathology Russell Raff Harvey Rand Eli Zukovsky Pete Beausoleil Venkat Iyer Jen Flaherty Baxter J Garcia, Ph.D.

Unconventional or a unicorn 🦄?! This week I was reminded how important it is to own the narrative and tell your story well. I've always shared my non-traditional unconventional path to sales leadership (clinical scientist to VP of Sales). I had someone I respect challenge the story I was telling myself and others. It's what made me a unicorn and was my superpower! Why? My commercial launch started with me selling directly to pathologists because I knew pathology (Fun Fact: I have assisted in 100 autopsies and was on a journey to become a forensic pathologist). I've influenced over $100M in revenue across LifeSciences, Oncology, Technology, and Professional Services over the past 15 years. What story have you been sharing that might need tweaking?! #ownyourjourney #storytelling #leadership #sales

Our CEO Scott Nelson recently published an op-ed for MD+DI on how to get to yes with FDA. In addition to the 5 key learnings he featured from other #medtech entrepreneurs, he also touches on: 👁️🗨️ How to decide if your idea has legs. 🔎 What ruthless decision-making looks like during early development phases. 👭🏽 An alternative way of engaging with regulatory bodies. Click on the link ⬇ for a closer look at these key learnings from #medtech entrepreneurs.

Edwards on M&A Spree with Another Big Move 🌟 Exciting times in the MedTech world! Edwards Lifesciences has acquired Genesis MedTech's transcatheter aortic valve replacement (TAVR) system aimed at treating severe aortic regurgitation. They've also invested $25 million to support Genesis' product and market development efforts. This acquisition is part of Edwards' broader strategy, following their recent high-profile buys. Just last month, they spent $1.2 billion on JenaValve Technology and Endotronix and exercised a $300 million option to buy Innovalve Bio Medical. Amid concerns about TAVR volumes, Edwards is doubling down, reinforcing its competitive stance in the market. For companies and executives in MedTech and HealthTech, this is a fascinating time. Seeing a major player like Edwards make such bold moves provides a unique perspective on market dynamics and opportunities. What do you think of their aggressive expansion? Drop your thoughts below 👇 #MedTech #MergersAndAcquisitions #TAVR

We are excited to announce that Impilo, a leading investment company specializing in healthcare, has acquired Qufora in partnership with our existing shareholders.   With Impilo as investor and partner, we are ready to take the next step in our expansive business strategy. Nicholas Hooge, Partner at Impilo, says about the investment: “We have followed Qufora for several years and are highly impressed by the company’s development, which is largely grounded in Qufora’s strong values, strategy, and culture. This is encapsulated by a highly skilled management team and staff who show a deep passion for Qufora’s products and mission. With this partnership, we can jointly accelerate the company’s future expansion.” And Lena Ehmsen Lachenmeier, CEO of Qufora A/S adds: “Through this investment and with Impilo as part of our ownership, we have gained an experienced healthcare investor who will provide us with a strong and steady hand in executing our strategy. This means we can continue to develop groundbreaking products and services which enable people with chronic bowel disorders to live a better life.”   As a result of Impilo's investment in Qufora, a new board of directors will be appointed, with Mikael Worning as Chairman. Mikael has had a long career in the medtech industry, holding several top executive positions at Demant, as well as board positions at Ambu, 3Shape, Tandlægen.dk, and Cellavision. Find the full press release here. #Investment #BowelIrrigation #BowelDysfunction 

Amplitude Vascular Systems (AVS) is a medical device company based in Boston, MA, focused on safely and effectively treating severely calcified arterial disease. AVS is backed by global investors including BioStar Capital and CUE Growth Partners to develop their innovative Pulse IVL System that has recently received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin its pivotal trial. Angie Volk, VP of Business Development, and Sean Gilligan, COO of AVS, join this episode of the #MedtechImpactPodcast to share about their team’s mission and how they are bringing this exciting technology to market. With Johnson & Johnson’s $13.3B acquisition earlier this year of Shockwave Medical, the IVL space is showing that it is currently one of the hottest in medtech. We discuss how AVS’s Pulse IVL System is being designed to easily deliver therapy across complex calcified lesions and reduce overall procedural costs, making it hugely attractive to potential future acquirers.   As former Boston Scientific colleagues, Angie and Sean have extensive industry experience including unique insights of building a winning culture. They are leveraging these learnings and their network to efficiently navigate their solution to patients across the globe. With two medtech veterans, this is a conversation brimming with helpful tips for any would-be entrepreneur that is sure to leave you informed and inspired. Tune in to learn more - https://lnkd.in/eEJXZhUm #IntravascularLithotripsy #IVL #Medtech #Startup #WinningCulture #KeepInnovating Kyle Kruse 🚀, Daniel Ventresca, Mark Toland, Robert Chisena, Jon George MD, MBA, Hitinder Gurm, Renu Virmani, Tony Das. MD, FACC, David Kandzari, Steven Yakubov, Louis A Cannon, MD, FACA, FACC, FACP, FSCAI, David Long, Hank Kucheman, Scott Nelson, Michael Bodner, Ziad Ali, Ryan Egeland, George Adams, Ingrid Masson, Ivan Lopez Ribulgo, Jordi BÚA NOVO, Konstantinos Stavroulakis.

 Mark Bezjak, President of the Americas, and Joe Urban, President of Knees for Zimmer Biomet, joined me in One60 Studios to discuss how Zimmer Biomet continues to drive forward and set the pace as a global medtech leader.   We discussed how Zimmer Biomet’s bold vision for maintaining its leadership in medtech embraces and is introducing first-in-category enabling technologies in pre-op, intra-op, and post-op care for their patients.   I love seeing this sector of the market push hard and take a bold approach to what healthcare should be.

Check out this interesting discussion with Zimmer Biomet’s Mark Bezjak and Joe Urban regarding the full digitization of the knee replacement journey for clinicians, patients and payors. Thanks for the Canary shout out Joe Mullings! #techmed #innovation